The Hong Kong-based CRDMO was selected from a competitive pool of 120 entries, with judges from academia and finance evaluating the firm on governance, carbon neutrality, and stakeholder transparency. This recognition reinforces the company’s Green CRDMO initiative, which integrates sustainability into every stage of biologics research and manufacturing.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, noted that these awards validate the firm’s focus on long-term business resilience through transparent disclosure. The company recently achieved validation for its greenhouse gas reduction targets from the Science Based Targets initiative, aligning its Scope 1, 2, and 3 emissions with a 1.5°C pathway. These achievements follow the firm’s inclusion on the 2026 Forbes China ESG 50 list, further cementing its position as a leader in sustainable pharmaceutical development.
Comments (0)
No comments yet. Be the first!